Biogen News and Research

RSS

Adimab initiates independent collaborations with Biogen Idec and Novo Nordisk

Adimab, LLC, a technology leader in the discovery of fully human antibodies, today announced the initiation of two independent collaborations with Biogen Idec and Novo Nordisk. Over the past two years, Adimab has established collaborations with multiple leading pharmaceutical companies, including: Merck, Roche, Novartis, Pfizer, Eli Lilly, Genentech, Human Genome Sciences, and now Biogen Idec and Novo Nordisk.

29 Aug 2011

Alnylam second quarter revenue decreases to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2011, and company highlights.

From Precision NanoSystems Inc. 2 Aug 2011

New enhanced MS ActiveSource for patients with multiple sclerosis

Biogen Idec today announced it has strengthened MS ActiveSource, its industry-leading suite of services for people with multiple sclerosis (MS), with the addition of new resources and support programs.

28 Jul 2011

Biogen Idec reports revenue of $1.2 billion for second quarter 2011

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its second quarter 2011 results.

26 Jul 2011

Swedish Orphan Biovitrum, Biogen Idec announce data of rFVIIIFc Phase 1/2a trial for hemophilia A

Biogen Idec and Swedish Orphan Biovitrum today announced Phase 1/2a trial data showing that the companies' long-lasting fully-recombinant factor VIII Fc fusion protein (rFVIIIFc) was well tolerated and demonstrated an approximately 1.7-fold increase in half-life compared with Advate, a commercially-available factor VIII product, in 16 previously-treated patients with severe hemophilia A.

26 Jul 2011

Biogen Idec's FAMPYRA receives EU conditional approval for treating functional impairment in MS

Biogen Idec announced today it has received conditional approval from the European Commission for FAMPYRA® (prolonged-release fampridine tablets) to improve walking in adult patients with multiple sclerosis who have walking disability.

25 Jul 2011

Amorfix fiscal 2011 net loss decreases to $3,330,437

Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced its operational and financial results for the year ended March 31, 2011, as well as financial results for the fourth quarter.

29 Jun 2011

PDL revises revenue guidance for second quarter 2011 to $122M

PDL BioPharma, Inc. (PDL) today revised its guidance for the second quarter ending June 30, 2011, to approximately $122 million, as compared with actual results of $120 million for the second quarter of 2010, an anticipated one percent year-over-year increase.

9 Jun 2011

EC approves Biogen Idec's AVONEX PEN to treat multiple sclerosis

Biogen Idec announced today that the European Commission (EC) has granted approval to AVONEX PEN for patients with relapsing multiple sclerosis (MS) and patients who have had a single demyelinating event.

7 Jun 2011

Positive data from Biogen Idec's AVONEX clinical trial on multiple sclerosis presented at CMSC 2011

Biogen Idec today announced the findings from a randomized, multicenter, dose-blinded clinical trial that evaluated the effect of AVONEX dose titration, or gradual dose escalation, on flu-like symptoms associated with the therapy.

6 Jun 2011

Protox reports net and comprehensive loss of $2.2 million for first quarter 2011

Protox Therapeutics Inc., a leader in the development of receptor targeted therapeutic fusion proteins, today announced financial results and achievements for the quarter ended March 31, 2011.

2 Jun 2011

Biogen Idec joins global multiple sclerosis community to celebrate third annual World MS Day

Today, Biogen Idec will join the global multiple sclerosis (MS) community in celebrating the third annual World MS Day. Biogen Idec continues to be the industry leader in researching and providing groundbreaking therapies for MS. So far in 2011, the company has brought more hope to MS patients through a number of significant milestones.

25 May 2011

Biogen Idec launches educational forum, 'Women in MS'

Biogen Idec today announced the launch of "Women in MS," an educational initiative to address both the advantages and challenges female clinicians experience in treating patients living with multiple sclerosis.

25 May 2011

EMA CHMP recommends conditional marketing authorization of FAMPYRA

The Committee for Medicinal Products for Human Use of the European Medicine Agency has recommended conditional marketing authorization of FAMPYRA (prolonged-release fampridine 10 mg tablets) for the improvement of walking in adult patients with multiple sclerosis with walking disability.

20 May 2011

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

The Australian Therapeutic Goods Administration (TGA) has granted approval for FAMPYRA, (fampridine) 10 mg Modified Release (MR) tablet, for the symptomatic improvement of walking ability in adult patients with multiple sclerosis (MS) who have shown improvement after eight weeks of treatment.

16 May 2011

EMA agrees to Swedish Orphan Biovitrum, Biogen Idec's pediatric rFIXFc trial in hemophilia

Biogen Idec and Swedish Orphan Biovitrum today announced that the European Medicines Agency's Pediatric Committee has adopted an opinion agreeing to the pediatric investigational plan for the companies' long-lasting, fully-recombinant Factor IX Fc fusion protein.

9 May 2011

Acorda reports $0.7 million GAAP net loss for first quarter 2011

Acorda Therapeutics, Inc. today announced its financial results for the first quarter ended March 31, 2011.

5 May 2011

Decision Resources: 63% of neurologists select Tysabri as effective MS treatment

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the majority of surveyed U.S. neurologists selected Biogen Idec/Elan's Tysabri as the most effective therapy for the treatment of relapsing-remitting multiple sclerosis, when compared to other currently available agents.

22 Apr 2011

Biogen Idec first quarter revenues increase 9% to $1.2 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its first quarter 2011 results.

21 Apr 2011

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

Genentech, a member of the Roche Group and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) approved Rituxan® (rituximab), in combination with corticosteroids, as a new medicine for adults with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA).

20 Apr 2011